Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)
Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy a...
Gespeichert in:
| Veröffentlicht in: | Biochimica et biophysica acta. Reviews on cancer 2020-01, Vol.1873 (1), p.188318-188318, Article 188318 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 188318 |
|---|---|
| container_issue | 1 |
| container_start_page | 188318 |
| container_title | Biochimica et biophysica acta. Reviews on cancer |
| container_volume | 1873 |
| creator | Carmicheal, Joseph Patel, Asish Dalal, Vipin Atri, Pranita Dhaliwal, Amaninder S. Wittel, Uwe A. Malafa, Mokenge P. Talmon, Geoffrey Swanson, Benjamin J. Singh, Shailender Jain, Maneesh Kaur, Sukhwinder Batra, Surinder K. |
| description | Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.
[Display omitted] |
| doi_str_mv | 10.1016/j.bbcan.2019.188318 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6980327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304419X19301477</els_id><sourcerecordid>2311646957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c525t-83318c686a5b89d4797d30daa9b0fd256f8f8d734e13e2e5c71a911a2491da373</originalsourceid><addsrcrecordid>eNp9UcFq3DAQFaGl2Sb9gkDxMTl4q7FsWSo0EJa0DQRySSE3IUvjVBuvtJXshfx95W4akksummH05s2beYScAF0CBf5lvew6o_2yoiCXIAQDcUAWIFpZVg2Hd2RBGa3LGuTdIfmY0ppSaBjjH8ghA95yxuiC2MsBd3p0_r7Yam8i5twU5jHNYcDkgi_SGHO1dya_wX8tVlOM6MdCe1v00zhFfNWbU4xF58JGxweMp-nsmLzv9ZDw01M8Ir--X96ufpbXNz-uVhfXpWmqZiwFyysYLrhuOiFt3crWMmq1lh3tbd6pF72wLasRGFbYmBa0BNBVLcFq1rIjcr7n3U7dBq3JIqMe1Da6LOVRBe3U6x_vfqv7sFNcCsqqmeD0iSCGPxOmUW1cMjgM2mOYkqoYAK-5bGYo20NNDClF7J_HAFWzP2qt_vmjZn_U3p_c9fmlwuee_4ZkwLc9APOddg6jSsZhvqh1Ec2obHBvDvgLnImkmQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2311646957</pqid></control><display><type>article</type><title>Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Carmicheal, Joseph ; Patel, Asish ; Dalal, Vipin ; Atri, Pranita ; Dhaliwal, Amaninder S. ; Wittel, Uwe A. ; Malafa, Mokenge P. ; Talmon, Geoffrey ; Swanson, Benjamin J. ; Singh, Shailender ; Jain, Maneesh ; Kaur, Sukhwinder ; Batra, Surinder K.</creator><creatorcontrib>Carmicheal, Joseph ; Patel, Asish ; Dalal, Vipin ; Atri, Pranita ; Dhaliwal, Amaninder S. ; Wittel, Uwe A. ; Malafa, Mokenge P. ; Talmon, Geoffrey ; Swanson, Benjamin J. ; Singh, Shailender ; Jain, Maneesh ; Kaur, Sukhwinder ; Batra, Surinder K.</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.
[Display omitted]</description><identifier>ISSN: 0304-419X</identifier><identifier>EISSN: 1879-2561</identifier><identifier>DOI: 10.1016/j.bbcan.2019.188318</identifier><identifier>PMID: 31676330</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Biomarker ; Biomarkers, Tumor - analysis ; Carcinoma, Pancreatic Ductal - diagnosis ; Disease Progression ; Early detection ; Early Detection of Cancer - methods ; IPMN ; Pancreas - pathology ; Pancreatic cancer ; Pancreatic Cyst - diagnosis ; Pancreatic cystic lesions ; Pancreatic ductal adenocarcinoma ; Pancreatic Neoplasms - diagnosis ; Precancerous Conditions - diagnosis ; Radiomics ; Risk Factors ; Survival Analysis</subject><ispartof>Biochimica et biophysica acta. Reviews on cancer, 2020-01, Vol.1873 (1), p.188318-188318, Article 188318</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c525t-83318c686a5b89d4797d30daa9b0fd256f8f8d734e13e2e5c71a911a2491da373</citedby><cites>FETCH-LOGICAL-c525t-83318c686a5b89d4797d30daa9b0fd256f8f8d734e13e2e5c71a911a2491da373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbcan.2019.188318$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31676330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carmicheal, Joseph</creatorcontrib><creatorcontrib>Patel, Asish</creatorcontrib><creatorcontrib>Dalal, Vipin</creatorcontrib><creatorcontrib>Atri, Pranita</creatorcontrib><creatorcontrib>Dhaliwal, Amaninder S.</creatorcontrib><creatorcontrib>Wittel, Uwe A.</creatorcontrib><creatorcontrib>Malafa, Mokenge P.</creatorcontrib><creatorcontrib>Talmon, Geoffrey</creatorcontrib><creatorcontrib>Swanson, Benjamin J.</creatorcontrib><creatorcontrib>Singh, Shailender</creatorcontrib><creatorcontrib>Jain, Maneesh</creatorcontrib><creatorcontrib>Kaur, Sukhwinder</creatorcontrib><creatorcontrib>Batra, Surinder K.</creatorcontrib><title>Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)</title><title>Biochimica et biophysica acta. Reviews on cancer</title><addtitle>Biochim Biophys Acta Rev Cancer</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.
[Display omitted]</description><subject>Biomarker</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma, Pancreatic Ductal - diagnosis</subject><subject>Disease Progression</subject><subject>Early detection</subject><subject>Early Detection of Cancer - methods</subject><subject>IPMN</subject><subject>Pancreas - pathology</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Cyst - diagnosis</subject><subject>Pancreatic cystic lesions</subject><subject>Pancreatic ductal adenocarcinoma</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Precancerous Conditions - diagnosis</subject><subject>Radiomics</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><issn>0304-419X</issn><issn>1879-2561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFq3DAQFaGl2Sb9gkDxMTl4q7FsWSo0EJa0DQRySSE3IUvjVBuvtJXshfx95W4akksummH05s2beYScAF0CBf5lvew6o_2yoiCXIAQDcUAWIFpZVg2Hd2RBGa3LGuTdIfmY0ppSaBjjH8ghA95yxuiC2MsBd3p0_r7Yam8i5twU5jHNYcDkgi_SGHO1dya_wX8tVlOM6MdCe1v00zhFfNWbU4xF58JGxweMp-nsmLzv9ZDw01M8Ir--X96ufpbXNz-uVhfXpWmqZiwFyysYLrhuOiFt3crWMmq1lh3tbd6pF72wLasRGFbYmBa0BNBVLcFq1rIjcr7n3U7dBq3JIqMe1Da6LOVRBe3U6x_vfqv7sFNcCsqqmeD0iSCGPxOmUW1cMjgM2mOYkqoYAK-5bGYo20NNDClF7J_HAFWzP2qt_vmjZn_U3p_c9fmlwuee_4ZkwLc9APOddg6jSsZhvqh1Ec2obHBvDvgLnImkmQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Carmicheal, Joseph</creator><creator>Patel, Asish</creator><creator>Dalal, Vipin</creator><creator>Atri, Pranita</creator><creator>Dhaliwal, Amaninder S.</creator><creator>Wittel, Uwe A.</creator><creator>Malafa, Mokenge P.</creator><creator>Talmon, Geoffrey</creator><creator>Swanson, Benjamin J.</creator><creator>Singh, Shailender</creator><creator>Jain, Maneesh</creator><creator>Kaur, Sukhwinder</creator><creator>Batra, Surinder K.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200101</creationdate><title>Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)</title><author>Carmicheal, Joseph ; Patel, Asish ; Dalal, Vipin ; Atri, Pranita ; Dhaliwal, Amaninder S. ; Wittel, Uwe A. ; Malafa, Mokenge P. ; Talmon, Geoffrey ; Swanson, Benjamin J. ; Singh, Shailender ; Jain, Maneesh ; Kaur, Sukhwinder ; Batra, Surinder K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c525t-83318c686a5b89d4797d30daa9b0fd256f8f8d734e13e2e5c71a911a2491da373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarker</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma, Pancreatic Ductal - diagnosis</topic><topic>Disease Progression</topic><topic>Early detection</topic><topic>Early Detection of Cancer - methods</topic><topic>IPMN</topic><topic>Pancreas - pathology</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Cyst - diagnosis</topic><topic>Pancreatic cystic lesions</topic><topic>Pancreatic ductal adenocarcinoma</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Precancerous Conditions - diagnosis</topic><topic>Radiomics</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carmicheal, Joseph</creatorcontrib><creatorcontrib>Patel, Asish</creatorcontrib><creatorcontrib>Dalal, Vipin</creatorcontrib><creatorcontrib>Atri, Pranita</creatorcontrib><creatorcontrib>Dhaliwal, Amaninder S.</creatorcontrib><creatorcontrib>Wittel, Uwe A.</creatorcontrib><creatorcontrib>Malafa, Mokenge P.</creatorcontrib><creatorcontrib>Talmon, Geoffrey</creatorcontrib><creatorcontrib>Swanson, Benjamin J.</creatorcontrib><creatorcontrib>Singh, Shailender</creatorcontrib><creatorcontrib>Jain, Maneesh</creatorcontrib><creatorcontrib>Kaur, Sukhwinder</creatorcontrib><creatorcontrib>Batra, Surinder K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biochimica et biophysica acta. Reviews on cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carmicheal, Joseph</au><au>Patel, Asish</au><au>Dalal, Vipin</au><au>Atri, Pranita</au><au>Dhaliwal, Amaninder S.</au><au>Wittel, Uwe A.</au><au>Malafa, Mokenge P.</au><au>Talmon, Geoffrey</au><au>Swanson, Benjamin J.</au><au>Singh, Shailender</au><au>Jain, Maneesh</au><au>Kaur, Sukhwinder</au><au>Batra, Surinder K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s)</atitle><jtitle>Biochimica et biophysica acta. Reviews on cancer</jtitle><addtitle>Biochim Biophys Acta Rev Cancer</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>1873</volume><issue>1</issue><spage>188318</spage><epage>188318</epage><pages>188318-188318</pages><artnum>188318</artnum><issn>0304-419X</issn><eissn>1879-2561</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC) is an incredibly deadly disease with a 5-year survival rate of 9%. The presence of pancreatic cystic lesions (PCLs) confers an increased likelihood of future pancreatic cancer in patients placing them in a high-risk category. Discerning concurrent malignancy and risk of future PCL progression to cancer must be carefully and accurately determined to improve survival outcomes and avoid unnecessary morbidity of pancreatic resection. Unfortunately, current image-based guidelines are inadequate to distinguish benign from malignant lesions. There continues to be a need for accurate molecular and imaging biomarker(s) capable of identifying malignant PCLs and predicting the malignant potential of PCLs to enable risk stratification and effective intervention management. This review provides an update on the current status of biomarkers from pancreatic cystic fluid, pancreatic juice, and seromic molecular analyses and discusses the potential of radiomics for differentiating PCLs harboring cancer from those that do not.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>31676330</pmid><doi>10.1016/j.bbcan.2019.188318</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-419X |
| ispartof | Biochimica et biophysica acta. Reviews on cancer, 2020-01, Vol.1873 (1), p.188318-188318, Article 188318 |
| issn | 0304-419X 1879-2561 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6980327 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Biomarker Biomarkers, Tumor - analysis Carcinoma, Pancreatic Ductal - diagnosis Disease Progression Early detection Early Detection of Cancer - methods IPMN Pancreas - pathology Pancreatic cancer Pancreatic Cyst - diagnosis Pancreatic cystic lesions Pancreatic ductal adenocarcinoma Pancreatic Neoplasms - diagnosis Precancerous Conditions - diagnosis Radiomics Risk Factors Survival Analysis |
| title | Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A11%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevating%20pancreatic%20cystic%20lesion%20stratification:%20Current%20and%20future%20pancreatic%20cancer%20biomarker(s)&rft.jtitle=Biochimica%20et%20biophysica%20acta.%20Reviews%20on%20cancer&rft.au=Carmicheal,%20Joseph&rft.date=2020-01-01&rft.volume=1873&rft.issue=1&rft.spage=188318&rft.epage=188318&rft.pages=188318-188318&rft.artnum=188318&rft.issn=0304-419X&rft.eissn=1879-2561&rft_id=info:doi/10.1016/j.bbcan.2019.188318&rft_dat=%3Cproquest_pubme%3E2311646957%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2311646957&rft_id=info:pmid/31676330&rft_els_id=S0304419X19301477&rfr_iscdi=true |